Prophylactic therapy with OKT3 does not affect donor specific reactivity of peripheral blood lymphocytes from heart transplant recipients.

[1]  A. Matas,et al.  EVIDENCE THAT IMPROVED LATE RENAL TRANSPLANT OUTCOME CORRELATES WITH THE DEVELOPMENT OF IN VITRO DONOR ANTIGEN‐SPECIFIC HYPOREACTIVITY , 1993, Transplantation.

[2]  H. Schuurman,et al.  Transplantation tolerance in heart transplant recipients as demonstrated by unresponsiveness in cell-mediated lympholysis. , 1992, Human immunology.

[3]  G. Persijn,et al.  Renal transplant patients with steroid withdrawal evaluated longitudinally for their donor--specific cytotoxic T cell reactivity. , 1991, Transplantation.

[4]  W. Weimar,et al.  Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis. Induced anti-idiotypic and anti-isotypic anti-OKT3 antibodies do not prohibit depletion of peripheral T cells due to second OKT3 treatment , 1991 .

[5]  M. Simoons,et al.  Sequential OKT3 and cyclosporine after heart transplantation : a randomized study with single and cyclic OKT3 , 1991 .

[6]  A. Zeevi,et al.  Propagation and characterization of lymphocytes from transplant biopsies. , 1991, Critical reviews in immunology.

[7]  F. Claas,et al.  Alloreactive lymphoid infiltrates in human heart transplants. Loss of class II-directed cytotoxicity more than 3 months after transplantation. , 1991, Human immunology.

[8]  P. Tan,et al.  Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen , 1990, The Journal of experimental medicine.

[9]  A. Matas,et al.  A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients. , 1990, Transplantation.

[10]  J. Bluestone,et al.  Activation of human T cells in vivo following treatment of transplant recipients with OKT3. , 1990, Transplantation.

[11]  W. Hop,et al.  Cytoimmunological monitoring of heart transplant recipients , 1990 .

[12]  T. Stijnen,et al.  Renal transplant patients monitored by the cell-mediated lympholysis assay. Evaluation of its clinical value. , 1989, Transplantation.

[13]  G. Feutren.  Cyclosporin A: recent developments in the mechanism of action and clinical application. , 1989, Current opinion in immunology.

[14]  D. Droz,et al.  Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. , 1986, Transplantation.

[15]  S. Flechner,et al.  THE USE OF CYCLOSPORINE IN LIVING‐RELATED RENAL TRANSPLANTATION: Donor‐Specific Hyporesponsiveness and Steroid Withdrawal , 1984, Transplantation.

[16]  P. Terasaki.  The beneficial transfusion effect on kidney graft survival attributed to clonal deletion. , 1984, Transplantation.

[17]  T. Mohanakumar,et al.  Alterations in human regulatory T lymphocytes subpopulations after renal allografting. , 1981, Journal of immunology.

[18]  G. Persijn,et al.  CELL‐MEDIATED LYMPHOLYSIS STUDIES IN RENAL ALLOGRAFT RECIPIENTS , 1981, Transplantation.

[19]  Van Wauwe Jp,et al.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. , 1980 .

[20]  J. Harris,et al.  Relationship of donor-specific mixed lymphocyte culture reactivity to graft function in recipients of cadaveric renal allografts. , 1979, Clinical and experimental immunology.